Journal
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Volume 40, Issue 4, Pages 383-386Publisher
WILEY
DOI: 10.1111/ced.12540
Keywords
-
Categories
Funding
- Abbvie
- Actelion
- Amgen
- Celgene
- Lilly
- GSK-Stiefel
- Janssen
- MSD
- Novartis
- Pfizer
- Sandoz
- UCB
Ask authors/readers for more resources
Acne conglobata (AC) is a chronic, severe, inflammatory variant of acne characterized by development of cystic nodules, abscesses and sinus tracts. AC may prove resistant to conventional acne therapy. The off-label use of adalimumab for the treatment of AC has been reported recently. We present a 26-year-old man with AC resistant to conventional treatment, who was treated with 40mg adalimumab every otherweek, with significant clinical improvement. We review the evidence for the use of tumour necrosis factor antagonists in AC and related conditions. This case provides further evidence supporting the role of adalimumab in the treatment of AC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available